A pre-seed to Series A deep tech venture capital firm. We deploy capital and operator depth to build life-sciences infrastructure, reindustrialize America, and define the future of human–machine interaction.
Two decades of running real businesses across biopharma distribution, cross-border supply chain, manufacturing, and platform trading inform every check we write. For deep tech founders building in biotech and life sciences, our affiliated operating company is one of China’s leading biopharma distribution platforms, with direct access to over 1,000 pharma, biotech, CRO, CDMO, and research buyers across Asia. For hard-tech and human–machine interaction founders, we bring operator pattern recognition on the surfaces that decide whether a deep tech venture turns into a real company: manufacturing, regulation, distribution, and cross-border execution. See how we partner →
A concentrated active deep tech book. Specifics on terms, valuations, and competitive details are not disclosed publicly.
Founders engage Yan Ventures and our operating partner at four levels of depth, determined by fit with our investment thesis and product catalog. See the full partnership model →
A working conversation with a team that has actually run the kind of business you’re building. Open to any company that reaches out.
Our operating partner’s sales team surveys real pharma, biotech, CRO, and CDMO buyers across Asia to test live demand.
Hands-on demos with end users at CDMOs and pharma companies in one of the world’s largest biopharma markets.
Our operating partner becomes your commercial motor across China: regulatory, logistics, sales, and customer success.
We hold concentrated, move at founder speed, and bring twenty years of operator depth across biopharma, manufacturing, and cross-border execution. If you’re building deep tech toward a long-term problem that matters, send us a paragraph. We respond the same week.
jesse [at] yanvc [dot] com